QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Forecast, Price & News

$59.24
+2.50 (+4.41%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$57.62
$59.84
50-Day Range
$48.93
$73.47
52-Week Range
$38.86
$102.99
Volume
139,767 shs
Average Volume
210,260 shs
Market Capitalization
$1.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
30 days | 90 days | 365 days | Advanced Chart
Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech logo

About Krystal Biotech

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
119
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$26.69 per share

Profitability

Net Income
$-69.57 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,072,000
Market Cap
$1.52 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/17/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

350th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

55th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech
or view top-rated stocks.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Krystal Biotech
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings data on Monday, May, 9th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.10.
View Krystal Biotech's earnings history
.

What price target have analysts set for KRYS?

6 brokers have issued 1 year price objectives for Krystal Biotech's stock. Their forecasts range from $93.00 to $110.00. On average, they expect Krystal Biotech's share price to reach $101.60 in the next year. This suggests a possible upside of 71.5% from the stock's current price.
View analysts' price targets for Krystal Biotech
or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, Pres & CEO (Age 57, Pay $1.01M)
  • Ms. Suma M. Krishnan, Founder, COO, Pres of R&D and Director (Age 57, Pay $708.56k) (LinkedIn Profile)
  • Ms. Kathryn A. Romano, Exec. VP & Chief Accounting Officer (Age 40, Pay $452.43k)
  • Dr. Jing L. Marantz M.B.A., M.D., Ph.D., Exec. VP & Chief Bus. Officer (Age 57, Pay $46.7k)
  • Dr. Andreas C. Orth, Exec. VP & Chief Commercial Officer (Age 52, Pay $549.17k)
  • Ms. Gloria Lin, Accounting Mang.
  • Ms. Meg Dodge, VP of Investor Relations & Corp. Communications
  • Mr. David Glynn, Gen. Counsel, Commercial & Compliance
  • Mr. John Karakkal, VP of North American Sales & Marketing
  • Ms. Katherine Tuminello, HR & Office Mang.
What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.68%), Lord Abbett & CO. LLC (4.60%), State Street Corp (4.17%), Vanguard Group Inc. (4.10%), Frazier Life Sciences Management L.P. (3.38%) and First Light Asset Management LLC (2.80%).
View institutional ownership trends for Krystal Biotech
.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Jane Street Group LLC, Verition Fund Management LLC, Cutler Group LP, Simplex Trading LLC, Citigroup Inc., Jacob Asset Management of New York LLC, and Kynam Capital Management LP.
View insider buying and selling activity for Krystal Biotech
or view top insider-selling stocks.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., State Street Corp, Hood River Capital Management LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., BlackRock Inc., Jennison Associates LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Krystal Biotech
or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $59.24.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.52 billion. The company earns $-69.57 million in net income (profit) each year or ($4.37) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 119 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.